Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Analysts Estimate Phibro Animal Health (PAHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) to Post Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.
Looking for a Growth Stock? 3 Reasons Why Haemonetics (HAE) is a Solid Choice
by Zacks Equity Research
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Haemonetics (HAE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.
What Makes Haemonetics (HAE) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include Clarivate, Expedia Group and Haemonetics
by Zacks Equity Research
Clarivate, Expedia Group and Haemonetics are part of the Zacks Screen of the Week article.
HCA Healthcare (HCA) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.
Time To Pick These 3 Top Relative Price Strength Stocks
by Nilanjan Choudhury
Clarivate Plc (CLVT), Expedia Group (EXPE) and Haemonetics Corporation (HAE) are three stocks with explosive relative price strength.
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
Company News for Nov 8, 2022
by Zacks Equity Research
Companies In The News Are: HAE, AMG, NI, PLTR.
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 18.57% and 8.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Haemonetics (HAE) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
by Zacks Equity Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
by Zacks Equity Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.